Elena Cattaneo Selected Research

Huntington Disease (Huntington's Disease)

11/2021	SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington's disease phenotypes.
10/2021	Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease.
1/2021	ADAM10 hyperactivation acts on piccolo to deplete synaptic vesicle stores in Huntington's disease.
10/2020	Striatal infusion of cholesterol promotes dose-dependent behavioral benefits and exerts disease-modifying effects in Huntington's disease mice.
1/2020	Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease.
1/2020	New label-free methods for protein relative quantification applied to the investigation of an animal model of Huntington Disease.
12/2017	Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation.
2/2017	Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington's disease: A cross-validation study in Q175 knock-in mice.
12/2015	Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice.
12/2014	Repressor element-1 silencing transcription factor (REST) is present in human control and Huntington's disease neurones.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elena Cattaneo Research Topics

Disease

63	Huntington Disease (Huntington's Disease) 11/2021 - 10/2002
30	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2021 - 01/2003
5	Neoplasms (Cancer) 02/2009 - 03/2003
4	Alzheimer Disease (Alzheimer's Disease) 06/2009 - 02/2005
3	Parkinson Disease (Parkinson's Disease) 01/2015 - 04/2007
3	Nervous System Diseases (Neurological Disorders) 09/2013 - 05/2002
3	Disease Progression 11/2008 - 09/2003
2	Cognitive Dysfunction 10/2021 - 01/2021
2	Glioma (Gliomas) 02/2009 - 05/2003
2	Glioblastoma (Glioblastoma Multiforme) 02/2009 - 08/2005
2	Brain Diseases (Brain Disorder) 11/2006 - 05/2005
1	Bronchiolitis Obliterans Syndrome 01/2022
1	Autosomal Dominant Adult-Onset Demyelinating Leukodystrophy 01/2019
1	Infections 10/2016
1	Neuroinflammatory Diseases 04/2014
1	Bipolar Disorder (Manic Depressive Psychosis) 12/2012
1	Chromosome Aberrations (Chromosome Abnormalities) 08/2011
1	Mitochondrial Diseases (Mitochondrial Disease) 02/2008
1	Polyps 11/2006
1	Stroke (Strokes) 04/2006
1	Traumatic Brain Injuries (Traumatic Brain Injury) 04/2006
1	Astrocytoma (Pilocytic Astrocytoma) 08/2005
1	Brain Neoplasms (Brain Tumor) 05/2003
1	Breast Neoplasms (Breast Cancer) 03/2003

Drug/Important Bio-Agent (IBA)

17	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2003
14	CholesterolIBA 11/2021 - 10/2005
14	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2014 - 09/2003
9	polyglutamineIBA 04/2014 - 10/2002
6	Huntingtin ProteinIBA 12/2017 - 09/2003
5	Pharmaceutical PreparationsIBA 12/2012 - 09/2005
4	Biological ProductsIBA 01/2021 - 11/2006
4	Nerve Growth Factors (Neurotrophins)IBA 06/2009 - 01/2003
3	RE1-silencing transcription factorIBA 12/2014 - 06/2007
2	MicroRNAs (MicroRNA)IBA 01/2022 - 03/2008
2	EndocannabinoidsIBA 07/2013 - 07/2007
2	Complement System Proteins (Complement)IBA 08/2011 - 11/2008
2	ElementsIBA 01/2010 - 08/2007
2	Transcription Factors (Transcription Factor)IBA 01/2010 - 06/2007
2	3,9-bis((ethylthio)methyl)-K-252aIBA 09/2008 - 09/2008
2	Messenger RNA (mRNA)IBA 09/2008 - 10/2007
2	Amino Acids FDA Link 02/2008 - 11/2006
2	ChromatinIBA 11/2007 - 06/2007
2	Quinolinic AcidIBA 11/2004 - 01/2003
2	Biomarkers (Surrogate Marker)IBA 11/2003 - 03/2003
1	Dopamine Receptors (Dopamine Receptor)IBA 11/2021
1	ADAM10 ProteinIBA 01/2021
1	Small Molecule LibrariesIBA 01/2021
1	Lamin Type B (Lamin B)IBA 01/2019
1	Dopamine (Intropin)FDA LinkGeneric 01/2015
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 11/2014
1	CytokinesIBA 04/2014
1	LithiumIBA 12/2012
1	Neuroprotective AgentsIBA 12/2012
1	PPAR gammaIBA 06/2011
1	OligonucleotidesIBA 02/2011
1	Histone Deacetylases (Histone Deacetylase)IBA 09/2010
1	Untranslated RNA (Noncoding RNA)IBA 05/2010
1	GlycosaminoglycansIBA 07/2009
1	Temozolomide (Temodar)FDA LinkGeneric 02/2009
1	HeterochromatinIBA 02/2009
1	DNA (Deoxyribonucleic Acid)IBA 02/2009
1	Carmustine (FIVB)FDA Link 02/2009
1	O-(6)-methylguanineIBA 02/2009
1	24-hydroxycholesterolIBA 11/2008
1	Environmental BiomarkersIBA 11/2008
1	2-aminothiazoleIBA 05/2008
1	Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA 04/2008
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 04/2008
1	Phosphatidylinositols (Phosphatidylinositol)IBA 02/2008
1	Inositol (Myoinositol)IBA 02/2008
1	CalciumIBA 02/2008
1	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 07/2007
1	UbiquitinIBA 02/2007
1	Proteasome Endopeptidase Complex (Proteasome)IBA 02/2007
1	Amyloid beta-PeptidesIBA 11/2006
1	EnzymesIBA 11/2006
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 07/2006
1	Tyrosine (L-Tyrosine)FDA Link 08/2005
1	Amyloid (Amyloid Fibrils)IBA 02/2005
1	gamma-Aminobutyric Acid (GABA)IBA 11/2004
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 11/2003
1	CaspasesIBA 09/2003
1	Minocycline (Cyclops)FDA LinkGeneric 09/2003
1	Cytochromes c (Cytochrome c)IBA 09/2003
1	Apoptosis Inducing FactorIBA 09/2003
1	Cytosine DeaminaseIBA 05/2003
1	Fluorouracil (Carac)FDA LinkGeneric 05/2003
1	ProdrugsIBA 05/2003
1	Flucytosine (Ancobon)FDA Link 05/2003
1	ParaffinIBA 03/2003
1	Formaldehyde (Formol)FDA Link 03/2003
1	Ciliary Neurotrophic Factor (CNTF)IBA 01/2003
1	Apomorphine FDA Link 01/2003

Therapy/Procedure

9	Therapeutics 01/2022 - 05/2002
4	Transplantation 01/2015 - 05/2003
1	Photopheresis 01/2022
1	Injections 10/2021
1	Cell Transplantation 04/2006